Skip to main content
. 2022 Feb 20;62(3):374–382. doi: 10.1111/head.14255

FIGURE 3.

FIGURE 3

Results of thresholding exercise in participants with episodic migraine. (A) Reduction in likelihood of migraine on day 1 that has the equivalent value as reduction of 1 migraine days during the first month of treatment. (B) Reduction in monthly migraine days that has the equivalent value as the 8% reduction in the likelihood of a migraine on day 1 observed between eptinezumab and placebo in the PROMISE‐1 trial. 14 , 15 MMD, monthly migraine day [Color figure can be viewed at wileyonlinelibrary.com]